March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
October 2010 in “Journal of Men's Health” Larger prostate size in older men may be linked to poorer semen quality and fertility issues.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
January 2022 in “Skin appendage disorders” Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.
September 2019 in “Human Andrology” Higher serum androgens contribute to male pattern baldness.
August 2019 in “Journal of The American Academy of Dermatology” No link found between hair loss severity and PSA levels in men.
January 2018 in “프로그램북(구 초록집)” No link between hair loss severity and PSA levels in men.
January 2017 in “Indian journal of health sciences and biomedical research KLEU” There is no link between hair loss and prostate enlargement.
March 2013 in “The Journal of Urology” Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.
April 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.
March 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Hair loss can be an early sign of prostate enlargement.
September 2005 in “Archives of Dermatological Research” Large prostate patients more likely to have hair loss.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
February 2007 in “Lancet Oncology” Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
April 2013 in “The Journal of Urology” Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
March 2026 in “Translational Andrology and Urology” Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
January 2010 in “CommonKnowledge Research Repository (Pacific University Oregon)” Finasteride can't be recommended for cancer prevention due to concerns about high-grade cancer risk.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
75 citations
,
May 1986 in “Clinics in endocrinology and metabolism” Male hormones are important for hair and oil gland development and can cause conditions like excessive hair growth and acne.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.